AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00500253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchial hyperresponsiveness with methacholine (PC20M)
Description: bronchial hyperresponsiveness with methacholine (PC20M)
Study NCT00500253 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchial hyperresponsiveness with methacholine (PC20M)
Description: bronchial hyperresponsiveness with methacholine (PC20M)
Study NCT00500253 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: symptom score diary (according to 2007 GINA guidelines)
Description: symptom score diary (according to 2007 GINA guidelines)
Study NCT01310582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study NCT01310582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT01227239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
Study NCT01227239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
Study NCT01227239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose is 50.4Gy (1.8Gy X 28 fractions)
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10mg PO daily continuously for all 28 days of a cycle
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
Study NCT00371176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO daily continuously for all 28 days of a cycle
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
Study NCT00915603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Study NCT03585712 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Norgestrel 0.075 mg
Description: Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
Study NCT00371176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study NCT04306393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: 80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine will be dosed as one 50 mg pill every day of each cycle.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perifosine Placebo
Description: Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
Study NCT01002248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
Study NCT03184129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trial group
Description: Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
Study NCT03184129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control group
Description: Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
Study NCT00594074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white wine
Description: 3.25 ounces of white wine twice a day with lunch and dinner
Study NCT01420042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
Study NCT01420042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lemon flavoured cordial and Water for Injection
Study NCT01288209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule taken by mouth once daily for 12 or 24 weeks.
Study NCT01288209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (PegIFNα-2a )
Description: PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
Study NCT01288209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Study NCT01573949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
Study NCT01882153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Description: The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, \& Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
Study NCT01882153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Therapy
Description: The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
Study NCT01882153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE and PRT Hybrid
Description: The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
Study NCT01461889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfuse plasma to High INR target
Description: Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
Study NCT01461889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfuse plasma to Low INR target
Description: Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
Study NCT00583466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Description: Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
Study NCT00583466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be injected under the lesion to create submucosal cushion
Study NCT00583466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPMC
Description: Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
Study NCT00351377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Sodium
Description: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
Study NCT00423813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral Solution
Study NCT00423813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: two doses
Study NCT02610530 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy with Ileal Transposition
Description: Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
Study NCT02610530 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy with Transit Bipartition
Description: Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
Study NCT02610530 — intervention group
Intervention type: OTHER
Intervention: Medical Treatment
Description: Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
Study NCT01408719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Minimal beta-glucan
Study NCT01408719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3g LMW beta-glucan
Description: 3grams beta-glucan
Study NCT00312585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT00312585 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Study NCT00731133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Disulfiram
Description: 250 mg/day
Study NCT00012064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
Study NCT03809039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345
Description: MT-6345
Study NCT03809039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345 Placebo
Description: MT-6345 Placebo
Study NCT00967967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medication Mometasone furoate and desloratadine
Description: One month treatment with both drugs
Study NCT03699189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate ANAIS
Description: ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting.
Study NCT04324216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D virtual reality and hands-on aromatherapy
Description: Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
Study NCT04550819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraintestinal extended biliary stents
Description: The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
Study NCT04550819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ordinary plastic biliary stents
Description: The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
Study NCT01408719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5g LMW beta-glucan
Description: 5 grams beta-glucan
Study NCT01408719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3g HMW beta-glucan
Description: 3 grams of high molecular weight beta-glucan
Study NCT01742715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP by Best oxygenation
Description: Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
Study NCT01742715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP by Best Compliance
Description: In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed.
Study NCT01742715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP by Esophageal pressure
Description: Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
Study NCT03334877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: β -human chorionic gonadotropin
Description: Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
Study NCT02735304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Impression intervention
Description: The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
Study NCT01173900 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil® HPV vaccine
Description: 0.5 ml given at 0, 2, 6 months
Study NCT03849703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Intervention #1
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
Study NCT03849703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Intervention #2
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
Study NCT03849703 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Partial Intervention #1
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
Study NCT03849703 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Partial Intervention #2
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
Study NCT00830323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir + zanamivir
Description: oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
Study NCT00830323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir+ amantadine
Description: oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
Study NCT00830323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: oseltamivir (75mg bd for 5 days, oral)
Study NCT02403518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Spinal Cord Stimulator System
Study NCT03750864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-LCS Therapy
Description: All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance \& Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
Study NCT02671188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
Study NCT02671188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride) will be used as placebo.
Study NCT00322569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corio™ Pimecrolimus-Eluting Coronary Stent System
Description: Drug-eluting stent
Study NCT00322569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
Description: Drug-eluting stent
Study NCT00322569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Costar ™ Paclitaxel-Eluting Coronary Stent System
Description: Drug-eluting Stent
Study NCT02301338 — intervention group
Intervention type: OTHER
Intervention: Usual care
Study NCT02301338 — intervention group
Intervention type: OTHER
Intervention: Phone Calls
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 12 x 50mg tablet, oral, single dose
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 x 400mg capsule, oral, single dose
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 12 x matched to AZD5672 50 mg tablet
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 x matched to AZD5672 50 mg tablet
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 3 x 50mg tablet, oral. single dose
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 9 x matched to AZD5672 50mg tablet